Literature DB >> 15029232

B-cell-specific transgene expression using a self-inactivating retroviral vector with human CD19 promoter and viral post-transcriptional regulatory element.

M Werner1, J Kraunus, C Baum, T Brocker.   

Abstract

Retroviral gene transfer resulting in transgene expression selectively restricted to specific cell lineages would be desirable for many gene therapeutic applications. Such transcriptional targeting of retroviruses can be accomplished by employing eukaryotic control elements in self-inactivating (SIN) retroviral vectors, but use of these vectors is complicated by an accompanying reduction in viral titers. To overcome this restriction and address the influence of the post-transcriptional regulatory element of the Woodchuck hepatitis virus (WPRE) on viral titers and transgene expression, we developed SIN-vectors with and without WPRE. Using the enhancer-promoter of the Spleen Focus Forming virus (SFFV) to direct eGFP expression to multiple hematopoietic lineages, we show that WPRE significantly (>10 x) increased viral titers (>10(6) per ml of unconcentrated supernatant) and transgene expression in NIH3T3 cells in vitro. Gene expression in vivo was significantly lowered in lymphoid cells, but not in myeloid cells when WPRE was present. Furthermore, the use of WPRE in combination with the B-cell lineage-specific CD19 promoter significantly increased viral titers and allowed targeting of transgene expression by SIN-vectors specifically to B cells throughout their development in primary and secondary lymphoid organs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15029232     DOI: 10.1038/sj.gt.3302255

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  9 in total

1.  Gene therapeutic approach using mutation-adapted U1 snRNA to correct a RPGR splice defect in patient-derived cells.

Authors:  Esther Glaus; Fabian Schmid; Romain Da Costa; Wolfgang Berger; John Neidhardt
Journal:  Mol Ther       Date:  2011-02-15       Impact factor: 11.454

Review 2.  Lentiviral vectors for immune cells targeting.

Authors:  Steven Froelich; April Tai; Pin Wang
Journal:  Immunopharmacol Immunotoxicol       Date:  2010-06       Impact factor: 2.730

3.  Repopulation of B-lymphocytes with restricted gene expression using haematopoietic stem cells engineered with lentiviral vectors.

Authors:  T E Taher; C Tulone; R Fatah; F D'Acquisto; D J Gould; R A Mageed
Journal:  Gene Ther       Date:  2008-03-20       Impact factor: 5.250

4.  Generation of stable Xenopus laevis transgenic lines expressing a transgene controlled by weak promoters.

Authors:  Anne L'hostis-Guidet; Gaëlle Recher; Brigitte Guillet; Abdulrahim Al-Mohammad; Pascal Coumailleau; François Tiaho; Daniel Boujard; Thierry Madigou
Journal:  Transgenic Res       Date:  2009-04-30       Impact factor: 2.788

5.  Functional response to SDF1 alpha through over-expression of CXCR4 on adult subventricular zone progenitor cells.

Authors:  Xian Shuang Liu; Michael Chopp; Manoranjan Santra; Ann Hozeska-Solgot; Rui Lan Zhang; Lei Wang; Hua Teng; Mei Lu; Zheng Gang Zhang
Journal:  Brain Res       Date:  2008-06-14       Impact factor: 3.252

6.  Impact of age at administration, lysosomal storage, and transgene regulatory elements on AAV2/8-mediated rat liver transduction.

Authors:  Gabriella Cotugno; Patrizia Annunziata; Maria Vittoria Barone; Marianthi Karali; Sandro Banfi; Alberto Auricchio
Journal:  PLoS One       Date:  2012-03-13       Impact factor: 3.240

7.  Inhibition of histone deacetylation in 293GPG packaging cell line improves the production of self-inactivating MLV-derived retroviral vectors.

Authors:  Diana E Jaalouk; Milena Crosato; Pnina Brodt; Jacques Galipeau
Journal:  Virol J       Date:  2006-04-07       Impact factor: 4.099

8.  Elements of lentiviral vector design toward gene therapy for treating mucopolysaccharidosis I.

Authors:  Li Ou; Michael J Przybilla; Brenda L Koniar; Chester B Whitley
Journal:  Mol Genet Metab Rep       Date:  2016-08-13

9.  Combining Engineered U1 snRNA and Antisense Oligonucleotides to Improve the Treatment of a BBS1 Splice Site Mutation.

Authors:  Saskia Breuel; Mariann Vorm; Anja U Bräuer; Marta Owczarek-Lipska; John Neidhardt
Journal:  Mol Ther Nucleic Acids       Date:  2019-08-16       Impact factor: 8.886

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.